Compare InMode Ltd (INMD) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs Medpace Holdings Inc — how do they compare? InMode Ltd trades at $14.2 (market cap $809.93M), while Medpace Holdings Inc trades at $615.8 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 20.8× InMode Ltd's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, InMode Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold InMode Ltd for 28 Days and Medpace Holdings Inc for 14 Days on average.
| INMD | MEDP | |
|---|---|---|
Market Cap | $809.93M | $16.82B |
Volume | 365,490 | 223,093 |
Sector | Health | Health |
52-Week High | $16.62 | $630.19 |
52-Week Low | $12.76 | $393.42 |
Typical Hold Time | 28 Days | 14 Days |
Enterprise Value | $313.27M | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INMD trades at $14.20, up 1.36% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with 76.52% gross margins and 20.69% net income margin, though Q1 2026 earnings missed expectations. Recent news includes product innovation with Morpheus8 Cool launch and an unsolicited acquisition offer from Steel Partners at $16.75 per share. Analyst consensus is divided with 45% buy ratings amid ongoing shareholder activism concerns.
The stock presents value opportunity with attractive valuation multiples (P/E 11.63, EV/EBITDA 4.48) but faces near-term execution risks. Key catalysts include Q3 earnings delivery and resolution of acquisition talks, while risks involve management credibility and competitive pressures in aesthetic medicine markets.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
